Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.53
−$0.08 · -1.43%
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Previous close
$5.53
−$0.08 · -1.43%
After-hours
$5.53
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Day range
Current $5.53
52-week range
Current $5.53
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
20
Overpriced
Sentiment
68
Bullish
Risk
63
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Day range
Current $5.53
52-week range
Current $5.53
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 25.42M USD | 210.78M USD | 129.01M USD | — | — |
| Cost of goods sold | 4.1M USD | — | — | — | — |
| Gross profit | 21.33M USD | 210.78M USD | 129.01M USD | — | — |
| Research and development | 142.27M USD | 125.31M USD | 99.88M USD | 66.61M USD | 35.93M USD |
| Selling, general, and administrative | 41.05M USD | 38.47M USD | 32.29M USD | 30.64M USD | 15.2M USD |
| Operating expenses | 177.32M USD | 163.77M USD | 132.18M USD | 97.25M USD | 51.13M USD |
| Interest income | — | 19.47M USD | 15.22M USD | 2.63M USD | — |
| Interest expense | — | — | — | 2.63M USD | — |
| Depreciation and amortization | 4.1M USD | 3.77M USD | 2.84M USD | 1.9M USD | 1.12M USD |
| Operating income | −156M USD | 47.01M USD | −3.16M USD | −97.25M USD | −51.13M USD |
| Net income | −143.75M USD | 65.63M USD | −6.69M USD | −94.62M USD | −51.16M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$14.00
153.16% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.72M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM4.39M0.01%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF2M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO1.19M0.01%18B USD0.06%$112.1-0.10%
iShares Biotechnology ETFIBB1.01M0.01%10.41B USD0.44%$200.48-1.41%
Schwab U.S. Small-Cap ETFSCHA800.26K0.00%21.7B USD0.03%$32.66+0.15%
iShares Micro-Cap ETFIWC524.39K0.04%1.32B USD0.60%$182.79-0.31%
Dimensional - US Small Cap ETFDFAS481.06K0.00%33.66B USD0.31%$78.10+0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
